Publications by authors named "Ronald Bukowski"

Claim this Profile
O
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
Brian Rini, E Jason Abel, Laurence Albiges, Axel Bex, James Brugarolas, Ronald M Bukowski

Clin Genitourin Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer.
Michael W Kattan, Ronald M Bukowski

Front Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Brian I Rini, David F McDermott, Hans Hammers, William Bro, Ronald M Bukowski

J Immunother Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of inflammation in kidney cancer.
Antonio Roma de Vivar Chevez, James Finke, Ronald Bukowski

Adv Exp Med Biol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost of Hope: a candid roundtable discussion.
Amanda Bennett, Ronald M Bukowski, Keith Flaherty, J Cameron Muir, Craig D Turner

J Natl Compr Canc Netw· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, Theodore F Logan, Andrea L Harzstark, Ronald M Bukowski

J Clin Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
Sujata Patil, Judith Manola, Paul Elson, Sylvie Negrier, Bernard Escudier, Ronald Bukowski

J Urol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temsirolimus: a safety and efficacy review.
Ronald M Bukowski

Expert Opin Drug Saf· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genitourinary oncology: current status and future challenges.
Ronald M Bukowski

Front Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
Ronald M Bukowski

Front Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.
Susan A J Vaziri, Emmanuel J Tavares, Ali R Golshayan, Brian I Rini, Hakan Aydin, Ronald M Bukowski

Front Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
Dale R Shepard, Matthew M Cooney, Paul Elson, Ronald M Bukowski, Robert Dreicer

Invest New Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Jorge A Garcia, Tarek Mekhail, Paul Elson, Laura Wood, Ronald M Bukowski

BJU Int· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials.
Ram N Ganapathi, Ronald M Bukowski

Genome Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma.
Ronald M Bukowski

Cancer Manag Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Jean-Jacques Patard, Geraldine Pignot, Bernard Escudier, Tim Eisen, Axel Bex, Ronald Bukowski

Eur Urol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Christian Kollmannsberger, Georg Bjarnason, Patrick Burnett, Patricia Creel, Mellar Davis, Ronald Bukowski

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Judith Manola, Patrick Royston, Paul Elson, Jennifer Bacik McCormack, Madhu Mazumdar, Ronald Bukowski

Clin Cancer Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in renal cell carcinoma: what next?
Ronald M Bukowski

Curr Oncol Rep· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
Jorge A Garcia, Tarek Mekhail, Paul Elson, Pierre Triozzi, Cheryl Nemec, Ronald M Bukowski

BJU Int· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Jorge A Garcia, Thomas E Hutson, Paul Elson, C Lance Cowey, Timothy Gilligan, Ronald M Bukowski

Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of metastatic bone disease from genitourinary malignancies.
Peter F Mulders, Per-Anders Abrahamsson, Ronald M Bukowski

Expert Rev Anticancer Ther· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Ronald M Bukowski, Walter M Stadler, David F McDermott, Janice P Dutcher, Jennifer J Knox

Oncology· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.
Ronald M Bukowski

Cancer Manag Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis